FDA Approves 'Biosimilar' Drug Ogivri for Breast, Stomach Cancers

FRIDAY, Dec. 1, 2017 — Ogivri (tastuzumab-dkst) has been approved by the U.S. Food and Drug Administration as the nation’s first biosimilar drug to treat certain breast and stomach cancers, the agency said Friday in a news release.
The maker of a…
Source: Topamax